Effects of antihypertensive treatment on cerebral perfusion.
Antihypertensive treatment reduces the risk of ischemic strokes and cerebral hemorrhage as complications of excessive or long-standing hypertension. However, neurologic dysfunction and brain damage may also accompany short-term, and under certain conditions, even long-term antihypertensive treatment. Therefore, treatment should be instituted restrictively and cautiously. Special regard should be given to the action of antihypertensive drugs on cerebral perfusion in patients with an increased risk for the development of treatment-induced cerebral ischemic complications, such as patients with hypertensive encephalopathy or autonomic dysfunction, and elderly patients with suspected sclerotic stenosis of cerebral or neck arteries. The structural and functional lesions of cerebral vessels observed in acute and chronic hypertension are reviewed, as are the effects of antihypertensive drugs on cerebral blood flow. Calcium channel blockers and angiotensin-converting enzyme inhibitors may have advantages as first-line drugs in the treatment of patients with an elevated risk of cerebral hypoperfusion, because of the selective action of these agents on vasoconstricted vessels and their differential effects in varying regional vascular beds. The excellent efficacy of these drugs in the short- and long-term treatment of hypertension may lead to changes in the traditional management of hypertensive emergencies as well as in management strategies for other patients at risk for treatment-induced complications.
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000009:adverse effects; D002560:Cerebrovascular Circulation / Q000187:drug effects*; D003000:Clonidine / Q000009:adverse effects; D003981:Diazoxide / Q000009:adverse effects; D004232:Diuretics / Q000009:adverse effects; D006801:Humans; D006830:Hydralazine / Q000009:adverse effects; D006973:Hypertension / Q000188:drug therapy / Q000503:physiopathology; D005996:Nitroglycerin / Q000009:adverse effects; D009599:Nitroprusside / Q000009:adverse effects
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D004232:Diuretics; D009599:Nitroprusside; D006830:Hydralazine; D005996:Nitroglycerin; D003000:Clonidine; D003981:Diazoxide